Rise in adoption of genomics-focused pharmacology plays a great role in cancer treatment. Next-generation sequencing is one of the most advanced genomic technologies that are used to investigate genetic changes that drive progression of cancer. Global clinical oncology NGS market is driven by rapid technological advances in genomic technologies and sequencing platforms. The technique has emerged as a significant method to acquire a more accurate, and deep look into molecular foundations of individual tumors. In addition, rise in adoption of sequencing-based diagnostics platforms among practicing oncologists would further drive the market growth. Oncologists these days rely on NGS platforms to determine clinical actions including selection of drugs or their combinations. In fact, leading cancer centers, such as Mayo Clinic, and the Dana Farber Cancer Institute, have announced that they are now prepared to sequence “all patients for millions of tumor mutations”.
Additionally, exponential decrease in the costs for genetic sequencing would significantly propel the market growth. Therefore reduced cost coupled with technological advancements would enable the clinicians to get a complete catalog of disease genes. This would allow researchers and clinicians to look at the differences among genetic makeup of thousands of people and help discover critical cancer-causing genes.
Moreover, players are continuously involved in R&D to increase the number of constructed sequence reads per run. The sequencing platforms available today enable analysis of both RNA and DNA samples. Market players are focused to increase use of high throughput sequencing for clinical applications. Currently, they offer a diverse portfolio of NGS services to support a wide range of genomic applications, oncology being one of them. The laboratories are working in collaboration with NGS providers to provide a comprehensive array of services to the customers.
Data generated during sequencing of genome is used by clinicians to identify specific characteristics in patients as it is a good prognostic, and diagnostic tool. This contributes towards improvements in personalized medicine to patients, and improving the overall patient outcome. Moreover, studies suggest that NGS has the potential to transform future of oncology and enhance the potential of personalized medicine. Therefore, role of NGS in personalized medicine would provide lucrative opportunities for the market growth. Besides, the rise in trend for companion diagnostics would provide new avenues for growth of clinical oncology NGS market.
Some key participants are Illumina, Inc., Roche sequencing (454 Life Sciences), Agilent Technologies, Knome Inc., Genomatix Software GmbH, GATC Biotech Ag, Oxford Nanopore Technologies Ltd., Macrogen Inc., Life technologies Corp., DNASTAR Inc., Myriad Genetics, Exosome Diagnostics, Biomatters Ltd., BGI (Beijing Genomics Institute), Qiagen NV, Perkin Elmer, Inc., Pacific Bioscience, Inc., Partek, Inc., and Bio-Rad Laboratories, Inc.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."